To identify key factors influencing the effectiveness of platelet-rich plasma (PRP) therapy in treating elbow tendinopathy, a common degenerative condition.
Adults aged 19 years or older
Diagnosed with elbow tendinopathy
Persistent pain despite receiving conservative treatment
Individuals with systemic infection at the time of study participation
Patients with rheumatic diseases or inflammatory disorders
Individuals with unstable systemic conditions affecting the cardiovascular, gastrointestinal, respiratory, or endocrine systems
Any other cases deemed inappropriate for study participation by the investigator